M ore than 15 years ago, Cleveland et al 1 reported a preponderance of generalized bodily pain in patients with rhinitis. Conversely, a disproportionately high prevalence of chronic rhinosinusitis (CRS) symptoms among patients with otherwise unexplained bodily pain was noted in a study 2 of patients seeking general medical care. Confirmation of both observations has been evidenced by studies 3, 4 of patients with CRS using the 36-Item Short Form Health Survey (SF-36), a general health-related quality-of-life (QOL) instrument that includes a separate assessment of bodily pain.
Within one of the more commonly used global QOL survey instruments to measure changes following endoscopic sinus surgery (ESS), the bodily pain domain score of the SF-36 measures the frequency of and discomfort due to bodily pain on a scale of 0 (most bodily pain) to 100 (least bodily pain), permitting comparisons with general population norms. Geographically, culturally, and racially/ethnically diverse populations of patients with CRS show increased SF-36 bodily pain scores compared with norms. [3] [4] [5] [6] Fibromyalgia and other illnesses (eg, chronic fatigue syndrome, multiple chemical sensitivity syndrome, and sick building syndrome) commonly characterized by fatigue, bodily pain, and the absence of objective findings are commonly associated with an increased prevalence of CRS. 7, 8 One study demonstrated that 25 percent of patients with fibromyalgia had visited a physician within the previous 6 months for CRS-related problems. 9 Among many diverse medical specialties, clinicians have not generally accepted CRS as an independent and sufficient cause of bodily pain. This may prompt clinicians to look for and ascribe bodily pain symptoms to another condition aside from CRS, such as fibromyalgia. The possibility that some patients diagnosed with both fibromyalgia (or other functional somatic syndromes) and CRS are actually experiencing only CRS may not be considered.
Systematic assessments of the severity of bodily pain from CRS prior to ESS and the response of bodily pain to ESS have not been performed, to our knowledge. The objectives of this study were to determine if elevated levels of bodily pain are associated with CRS and to examine whether bodily pain improves following ESS.
MATERIALS AND METHODS

Identification of Studies
We searched PubMed, MEDLINE, EMBASE, Cochrane databases, Web of Science, and Google Scholar for all English-language peer-reviewed ESS studies of more than 10 adults from January 1, 1980, or database inception, to May 1, 2008. We used the following "exploded" Medical Subject Headings and text words: endoscopic, sinus, and surgery. Relevant reviews and cited references from retrieved articles were examined for additional studies. Issues of the American Journal of Rhinology not listed in Index Medicus (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) were searched by hand. After reviewing all titles and relevant abstracts for the reporting of ESS symptom outcomes, full-text articles were obtained for appropriate studies. We excluded studies involving surgery limited to the turbinates or septum, radical surgery (eg, frontal sinus drill-out or sinus ablation), surgery involving massive polyposis, and reports of results on patients with substantial comorbidities (eg, cystic fibrosis, human immunodeficiency virus, and malignancy).
Relevant unpublished data were also sought. We examined ISI Proceedings (accessed through Web of Science), contacted authors for additional data when necessary, and consulted investigators in the field.
Studies of all designs reporting symptom response following ESS were examined for any measurements of bodily pain. In addition, all survey instruments measuring generic or disease-specific QOL following ESS were examined for any questions related to bodily pain.
Studies reporting results on bodily pain were limited to those utilizing the SF-36, the 12-Item Short Form Health Survey (SF-12), or the 8-Item Short Form Health Survey (SF-8). The SF-36 reports QOL scores in eight domains from 0 (worst QOL) to 100 (best QOL) and measures bodily pain by scoring the response to two multiple-choice questions that, when combined, produce 11 possible levels of bodily pain severity. The SF-12 and the SF-8 are abbreviated versions of the SF-36. Using the already described methods, we searched for non-English-language studies with results measured by the SF-36, SF-12, or SF-8. After an independent search and assessment by two of us (A.C.C. and R.S.) and a group consultation, articles were catalogued.
Study Selection and Data Extraction
Using the guidelines provided by MOOSE (Meta-analysis of Observational Studies in Epidemiology), 10 two of the authors (A.C.C. and R.S.) independently reviewed all included studies measuring bodily pain before and after ESS. Using the PICOS (participant, intervention and exposure, comparator, outcomes, and study design) approach, the following characteristics of the studies and the participants were recorded: author, year, design, participants, surgical procedure, duration, purpose, survey methods, and specific symptoms analyzed. The time from surgery to the last evaluation of bodily pain was defined as the study duration. Study characteristics were entered into a spreadsheet (Excel 2003; Microsoft Corporation, Redmond, WA). Meta-analysis was performed using commercially available software (Comprehensive Meta-Analysis software version 2.2; Biostat, Inc, Englewood, NJ). 
Statistical Analysis
The standardized mean difference (Cohen d) of the SF-36 bodily pain domain scores before and after surgery using the exact sample size before and after surgery was defined as the effect size for outcome measures. Effect size in this study refers to the amount of improvement in bodily pain after ESS. Effect size is a standardized form of measuring the effect of an intervention adjusting for the pooled standard deviations of the outcome measures.
Because the correlation coefficient (r) between the paired measures before and after surgery (a statistic not generally published) is required for an optimal estimated effect size, we calculated the repeated standardized mean difference using appropriate formulas 11 provided by Comprehensive Meta-Analysis software version 2.2. The latter results are similar to Cohen d, especially for studies with the same sample size before and after surgery.
Bodily pain results were limited to studies reporting results using the SF-36 and SF-8. Therefore, this metaanalysis is limited to studies using these validated instruments. The combined effects for summarizing odds ratios and standardized mean differences were calculated using both the fixed method and the random-effects method. The SF-36 mean bodily pain domain scores were compared with normative values using 1-sample t test. For all results, P Ͻ 0.05 was considered statistically significant.
The SF-36 bodily pain scores were reported in nine studies 6, [12] [13] [14] [15] [16] [17] [18] [19] and were provided by the authors in two additional studies 20,21 (G. E. Davis, MD, MPH, e-mail communication, May 2008; and V. J. Lund, MS, FRCS, FRCS (Edin), written correspondence, December 2004). The SF-8 bodily pain domain scores were reported in a study 13 that was considered an SF-36 study. Three studies 12,17,21 among the 11 reported means but not standard deviations; when standard deviations were not specified and were unobtainable from the authors, they were estimated based on the other eight SF-36 bodily pain domain standard deviation scores (23.7 U before surgery and 21.9 U after surgery). When studies reported only the results of separate groups (eg, men and women), scores were weighted according to sample size and aggregated.
To evaluate whether the effects of ESS on bodily pain were the same across studies, heterogeneity was assessed. Heterogeneity was assessed using I 2 , a statistic that de- scribes the percentage of total variation across trials due to heterogeneity rather than chance, where I 2 lies between 0 percent (no heterogeneity) and 100 percent (maximal heterogeneity), with 25 percent, 50 percent, and 75 percent representing low, moderate, and high heterogeneity, respectively. 22 I 2 is calculated as I 2 ϭ 100 percent ϫ (Q Ϫ df)/Q, where Q indicates the Cochrane heterogeneity statistic.
RESULTS
Literature Search
After a review of 4553 articles identified by the prescribed searches and a full-text review of 424 articles, we found 279 studies that met initial selection criteria (Fig 1) . All survey instruments and other symptom scoring methods were examined for questions concerning bodily pain. Of 18 different survey instruments used in 279 articles, bodily pain was measured in four surveys: Glasgow Benefit Inventory (two studies), European Quality of Life (one study), SF-36 (13 studies), and SF-8 (one study). Independent scores for questions concerning bodily pain were not available for studies measuring results using the Glasgow Benefit Inventory or the European Quality of Life. No additional studies measured bodily pain by any other method.
Measures of bodily pain before and after ESS applicable to this meta-analysis were limited to 11 studies using the SF-36 (10 studies) or SF-8 surveys (one study) ( Table 1) . One non-English-language study 6 was translated by Dr. Rusan Chen, senior statistician, Georgetown University. The other non-English-language study 17 was translated by Steven Vitek, technical translator, PatentTranslators.com. (Copies of both translations are available from the corresponding author.)
Two studies 23, 24 reported SF-12 results using a version that did not include bodily pain domain scores (M. Akarcay, MD, e-mail communication, January 2005; and S. J. Atlas, MD, e-mail communication, March 2007). Two studies reported results from an identical or overlapping database and were excluded. 25, 26 A study 27 reporting SF-36 results as medians rather than means was also excluded.
Study and Baseline Patient Characteristics
Although the purpose and design of the included studies varied, all measured bodily pain before and after ESS using within-subject comparisons. Study design, length of followup, sample size, and the mean age of the patients for each of the 11 studies are given in Table 1 .
The total sample size for the meta-analysis was 1019 patients (range, 39-150 patients per study), with a mean (SD) age of 42.6 (4.7) years during a mean (SD) follow-up of 10.1 (9.4) months (median, 6 months). Nine of 11 were prospective cohort studies. The mean and median percentage of women in each study was 50 percent (range, 28% 17 to 67% 14 ).
The percentage of patients with nasal polyposis presenting for surgery was noted in seven studies and ranged from 7 percent 19 to 55 percent 6 (median, 40%). A history of nasal surgery was stated as an exclusionary condition in three studies. [14] [15] [16] The percentage of patients presenting for surgery with a history of prior nasal surgery was noted in three studies (17%, 19 24%, 12 and 81% 18 ). Patients with serious comorbid diseases were specifically excluded from three studies, 14, 19, 21 and none of the other studies described patients with significant comorbid diseases. The surgical procedure in all studies was described as ESS but varied in extent depending on CT and endoscopic findings.
Quantitative Data Synthesis
The pooled mean preoperative SF-36 bodily pain domain score of the 11 included studies, weighted by sample size, was 0.89 SD below U.S. national or local population norms (P Ͻ 0.001), indicating a 24 percent greater burden of bodily pain when compared to these norms (Fig 2) . Bodily pain scores were also significantly less (indicating more bodily pain) than those of a general normative population 25 years older and were similar to those of a general normative population 75 years or older (Fig 3) .
Among 11 studies, two studies 13, 14 did not demonstrate a significant improvement in bodily pain domain scores following ESS. The remaining nine studies showed a statistically significant improvement in the postoperative bodily pain domain scores compared with preoperative levels. Figure 4 shows the results of the meta-analysis using a forest plot of effect size and 95 percent confidence interval for each study. The effect size ranged from 0.23 to 0.97. The combined effect sizes, defined as Cohen d, are 0.55 and 0.54 as estimated using the fixed model and the random-effects model, respectively, showing a moderate effect size as defined by Cohen. 28 A fixed-effects model assumes that ESS had similar effects across studies, while a random-effects model assumes that ESS may have different treatment effects across studies. The test of heterogeneity resulted in Q 10 ϭ 17.93 (P ϭ 0.06) with I 2 ϭ 44 percent, demonstrating moderate heterogeneity.
Following surgery, postoperative bodily pain scores improved to values similar to U.S. national or local population norms in seven studies. 6, 12, [16] [17] [18] [19] 21 The mean postoperative SF-36 bodily pain domain score for all studies was approximately 0.30 SD below U.S. or local population norms, indicating 9 percent more bodily pain in the postsurgical study group than in the normative populations.
DISCUSSION
Although often unrecognized, the burden of CRS-associated bodily pain is substantial, exceeding the burden of bodily 
Figure 4
Changes in SF-36 bodily pain scores following endoscopic sinus surgery. SF-36, 36-Item Short Form Health Survey. Data are given as standardized mean difference (95% confidence interval) unless otherwise indicated. Positive estimates favor decreased bodily pain following endoscopic sinus surgery. Effect size was defined as the standardized mean difference (Cohen d pain in a patient population norm 25 years older and similar to that of older patients, patients with depression, and patients having arthritis. The resulting QOL impairment due to bodily pain is well described by the SF-36; however, the prevalence of bodily pain is not. Cleveland et al 1 noted bodily pain among 49 percent in a series of 47 consecutive patients with rhinitis. Fibromyalgia diagnostic criteria were met in 38 percent of the study population. In a study of patients with chronic fatigue syndrome, 7 a syndrome defined, in part, by bodily pain and symptoms typical of CRS, 71 percent had symptoms of rhinitis.
Fatigue and bodily pain largely define a number of functional somatic syndromes that are poorly differentiated from each other, lack objective findings, and are characterized by a disproportionate prevalence of CRS (chronic fatigue syndrome, fibromyalgia, multiple chemical sensitivity syndrome, etc). Because undetected or undiagnosed CRS has not been a generally accepted explanation for otherwise unexplained bodily pain, it is likely that some patients are inappropriately classified as experiencing these functional somatic syndromes. These syndromes are associated with significant morbidity and respond poorly to treatment. The need to appropriately diagnose and treat CRS in patients with functional somatic syndromes is supported by our findings and by a recent report 29 demonstrating improvement in fatigue and QOL following ESS in patients with fibromyalgia.
The improvement in bodily pain noted in nine of 11 studies produced a moderate-sized combined effect of 0.55 (95% confidence interval, 0.45-0.64), corresponding to a mean (SD) improvement of 11.8 (6.1) U on the SF-36 bodily pain domain scale. This improvement reflects a change in the responses to two multiple-choice bodily pain domain questions of approximately one level (one net state change) among 11 possible levels of response. A combined effect of 0.5 SD such as that noted herein usually corresponds to a minimal clinically important difference in diseases for which a minimal clinically important difference has been established. 30 The effect size of ESS in relieving bodily pain is similar to the effect size of some established therapies in relieving the bodily pain of fibromyalgia (aerobic exercise effect size, 0.377; pool-based exercise effect size, 0.437; and tramadol hydrochloride effect size, 0.657). 31 In addition, the combined effect improvement noted for bodily pain is similar to the SF-36 vitality domain score combined effect of 0.47 (95% confidence interval, 0.38-0.56) as noted in a previous publication. 32 In that study, fatigue (vitality) improved after ESS to a similar degree as other pooled nasal symptoms, suggesting that bodily pain might also improve as much as other pooled nasal symptoms after surgery.
While bodily pain has been only minimally explored as a specific CRS symptom complex, one study 33 noted more bodily pain in patients with greater than 9 mm of sinus soft tissue swelling on computed tomography than in patients with 9 mm or less of swelling. While the conclusions of this meta-analysis are partially limited by the number, size, and design of the studies examined, they do nevertheless offer the most consistent evidence to date that bodily pain likely improves following ESS. Patients awaiting ESS for CRS who have significant bodily pain symptoms can expect a reasonable likelihood that their symptoms will show fairly substantial improvement after surgery.
CONCLUSIONS
Chronic rhinosinusitis is characterized by elevated levels of bodily pain in addition to more well-known symptoms. Following ESS, bodily pain improves by a pooled-effect size of approximately 0.5 SD, a statistically significant improvement similar to that noted in a previous meta-analysis 32 for fatigue.
